Meeting
2024 ASCO Genitourinary Cancers Symposium
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
Authors
Mathilde Cancel
Department of Medical Oncology, University Hospital, Tours, France
Mathilde Cancel , Jérémie Naffrichoux , Pierre Poupin , William Pouillot , Claude Linassier , Nathalie Rioux-Leclercq , Manon De Vries-Brilland , Loic Mourey , Brigitte Laguerre , Stephane Oudard , Marine Gross-Goupil , Gwenaelle Gravis , Frederic Rolland , Laura Moise , Sheik Muhummud Fardeen Emambux , Cecile Vassal , Sylvie Zanetta , Nicolas Penel , Laurence Albiges , Gaelle Fromont
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 463)
DOI
10.1200/JCO.2024.42.4_suppl.463
Abstract #
463
Poster Bd #
K4
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.
First Author: Katherine L. Pogue-Geile
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
The prognostic significance of PDL1 expression in locally advanced non-small-cell lung cancer (LA-NSCLC) treated with definitive intent.
First Author: Devarati Mitra
Poster
2023 ASCO Annual Meeting
Molecular and clinical correlates of DSCR1 expression in pancreatic cancer (PDAC).
First Author: Francesca Battaglin
Poster
2022 ASCO Annual Meeting
Comprehensive transcriptomic analysis of immune checkpoint markers in a pancancer cohort: Implications for response and resistance.
First Author: Hirotaka Miyashita